Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1986 Apr;64(1):80–87.

T cell function in systemic lupus erythematosus: normal production of and responsiveness to interleukin 2.

A M Draeger, A J Swaak, H G van den Brink, L A Aarden
PMCID: PMC1542159  PMID: 3488149

Abstract

To investigate the role of interleukin 2 (IL-2) in systemic lupus erythematosus (SLE) mononuclear cells (MNC) of 68 SLE patients were tested for their ability to produce and also to respond to IL-2. Cells were collected monthly over an one year period. IL-2 production by MNC was measured under various conditions after optimal and suboptimal stimulation. Although we found a large variation in IL-2 production by individual MNC preparations no statistical significant differences were found between normal and SLE cells. To study IL-2 responsiveness, proliferation of MNC was studied under conditions where endogenous IL-2 production is limiting. Addition of IL-2 resulted in a four- to eight-fold enhancement of proliferative responses. However also in this respect no differences were found between SLE patients and healthy controls. Thus, in this group of SLE patients no abnormalities in IL-2 production or response could be demonstrated.

Full text

PDF
80

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alcocer-Varela J., Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest. 1982 Jun;69(6):1388–1392. doi: 10.1172/JCI110579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Altman A., Theofilopoulos A. N., Weiner R., Katz D. H., Dixon F. J. Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2. J Exp Med. 1981 Sep 1;154(3):791–808. doi: 10.1084/jem.154.3.791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boyd A. W., Fisher D. C., Fox D. A., Schlossman S. F., Nadler L. M. Structural and functional characterization of IL 2 receptors on activated human B cells. J Immunol. 1985 Apr;134(4):2387–2392. [PubMed] [Google Scholar]
  4. Fauci A. S., Steinberg A. D., Haynes B. F., Whalen G. Immunoregulatory aberrations in systemic lupus erythematosus. J Immunol. 1978 Oct;121(4):1473–1479. [PubMed] [Google Scholar]
  5. Fuller-Farrar J., Hilfiker M. L., Farrar W. L., Farrar J. J. Phorbol myristic acetate enhances the production of interleukin 2. Cell Immunol. 1981 Feb;58(1):156–164. doi: 10.1016/0008-8749(81)90157-x. [DOI] [PubMed] [Google Scholar]
  6. Gattringer C., Huber H., Michlmayr G., Braunsteiner H. Normal suppressor-cell activity in systemic lupus erythematosus. A study on 26 cases. Immunobiology. 1982 Oct;163(1):48–52. doi: 10.1016/s0171-2985(82)80105-8. [DOI] [PubMed] [Google Scholar]
  7. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  8. Koretzky G. A., Daniele R. P., Nowell P. C. A phorbol ester (TPA) can replace macrophages in human lymphocyte cultures stimulated with a mitogen but not with an antigen. J Immunol. 1982 Apr;128(4):1776–1780. [PubMed] [Google Scholar]
  9. Korsmeyer S. J., Greene W. C., Cossman J., Hsu S. M., Jensen J. P., Neckers L. M., Marshall S. L., Bakhshi A., Depper J. M., Leonard W. J. Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci U S A. 1983 Jul;80(14):4522–4526. doi: 10.1073/pnas.80.14.4522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Krakauer R. S., Clough J. D., Alexander T., Sundeen J., Sauder D. N. Suppressor cell defect in SLE: relationship to native DNA binding. Clin Exp Immunol. 1980 Apr;40(1):72–76. [PMC free article] [PubMed] [Google Scholar]
  11. Larsson E. L., Iscove N. N., Coutinho A. Two distinct factors are required for induction of T-cell growth. Nature. 1980 Feb 14;283(5748):664–666. doi: 10.1038/283664a0. [DOI] [PubMed] [Google Scholar]
  12. Leonard W. J., Depper J. M., Uchiyama T., Smith K. A., Waldmann T. A., Greene W. C. A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature. 1982 Nov 18;300(5889):267–269. doi: 10.1038/300267a0. [DOI] [PubMed] [Google Scholar]
  13. Lightfoot R. W., Jr, Hughes G. R. Significance of persisting serologic abnormalities in SLE. Arthritis Rheum. 1976 Sep-Oct;19(5):837–843. doi: 10.1002/art.1780190501. [DOI] [PubMed] [Google Scholar]
  14. Linker-Israeli M., Bakke A. C., Kitridou R. C., Gendler S., Gillis S., Horwitz D. A. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol. 1983 Jun;130(6):2651–2655. [PubMed] [Google Scholar]
  15. Miedema F., Van Oostveen J. W., Sauerwein R. W., Terpstra F. G., Aarden L. A., Melief C. J. Induction of immunoglobulin synthesis by interleukin 2 is T4+/T8- cell dependent. A role for interleukin 2 in the pokeweed mitogen-driven system. Eur J Immunol. 1985 Feb;15(2):107–112. doi: 10.1002/eji.1830150202. [DOI] [PubMed] [Google Scholar]
  16. Mittler R., Rao P., Olini G., Westberg E., Newman W., Hoffmann M., Goldstein G. Activated human B cells display a functional IL 2 receptor. J Immunol. 1985 Apr;134(4):2393–2399. [PubMed] [Google Scholar]
  17. Miyasaka N., Nakamura T., Russell I. J., Talal N. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol. 1984 Apr;31(1):109–117. doi: 10.1016/0090-1229(84)90195-8. [DOI] [PubMed] [Google Scholar]
  18. Morimoto C., Abe T., Homma M. Altered function of suppressor T lymphocytes in patients with active systemic lupus erythematosus--in vitro immune response to autoantigen. Clin Immunol Immunopathol. 1979 Jun;13(2):161–170. doi: 10.1016/0090-1229(79)90060-6. [DOI] [PubMed] [Google Scholar]
  19. Morimoto C., Reinherz E. L., Abe T., Homma M., Schlossman S. F. Characteristics of anti-T-cell antibodies in systemic lupus erythematosus: evidence for selective reactivity with normal suppressor cells defined by monoclonal antibodies. Clin Immunol Immunopathol. 1980 Aug;16(4):474–484. doi: 10.1016/0090-1229(80)90189-0. [DOI] [PubMed] [Google Scholar]
  20. Muraguchi A., Kehrl J. H., Longo D. L., Volkman D. J., Smith K. A., Fauci A. S. Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function. J Exp Med. 1985 Jan 1;161(1):181–197. doi: 10.1084/jem.161.1.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nakamura T., Miyasaka N., Pope R. M., Talal N., Russell I. J. Immunomodulation by isoprinosine: effects on in vitro immune functions of lymphocytes from humans with autoimmune diseases. Clin Exp Immunol. 1983 Apr;52(1):67–74. [PMC free article] [PubMed] [Google Scholar]
  22. Newman B., Blank S., Lomnitzer R., Disler P., Rabson A. R. Lack of suppressor cell activity in systemic lupus erythematosus. Clin Immunol Immunopathol. 1979 Jun;13(2):187–193. doi: 10.1016/0090-1229(79)90063-1. [DOI] [PubMed] [Google Scholar]
  23. Palacios R. Mechanism of T cell activation: role and functional relationship of HLA-DR antigens and interleukins. Immunol Rev. 1982;63:73–110. doi: 10.1111/j.1600-065x.1982.tb00412.x. [DOI] [PubMed] [Google Scholar]
  24. Palacios R., Möller G. T cell growth factor abrogates concanavalin A-induced suppressor cell function. J Exp Med. 1981 May 1;153(5):1360–1365. doi: 10.1084/jem.153.5.1360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Robb R. J., Munck A., Smith K. A. T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med. 1981 Nov 1;154(5):1455–1474. doi: 10.1084/jem.154.5.1455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Rosenstreich D. L., Mizel S. B. Signal requirements for T lymphocyte activation. I. Replacement of macrophage function with phorbol myristic acetate. J Immunol. 1979 Oct;123(4):1749–1754. [PubMed] [Google Scholar]
  27. Sakane T., Kotani H., Takada S., Murakawa Y., Ueda Y. A defect in the suppressor circuits among OKT4+ cell populations in patients with systemic lupus erythematosus occurs independently of a defect in the OKT8+ suppressor T cell function. J Immunol. 1983 Aug;131(2):753–761. [PubMed] [Google Scholar]
  28. Sakane T., Steinberg A. D., Green I. Failure of autologous mixed lymphocyte reactions between T and non-T cells in patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3464–3468. doi: 10.1073/pnas.75.7.3464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Santoro T. J., Luger T. A., Ravache E. S., Smolen J. S., Oppenheim J. J., Steinberg A. D. In vitro correction of the interleukin 2 defect of autoimmune mice. Eur J Immunol. 1983 Jul;13(7):601–604. doi: 10.1002/eji.1830130717. [DOI] [PubMed] [Google Scholar]
  30. Sauerwein R. W., Van der Meer W. G., Dräger A., Aarden L. A. Interleukin 2 induces T cell-dependent IgM production in human B cells. Eur J Immunol. 1985 Jun;15(6):611–616. doi: 10.1002/eji.1830150615. [DOI] [PubMed] [Google Scholar]
  31. Sibbitt W. L., Jr, Kenny C., Spellman C. W., Ley K. D., Bankhurst A. D. Lymphokines in autoimmunity: relationship between interleukin-2 and interferon-gamma production in systemic lupus erythematosus. Clin Immunol Immunopathol. 1984 Aug;32(2):166–173. doi: 10.1016/0090-1229(84)90118-1. [DOI] [PubMed] [Google Scholar]
  32. Smeenk R., Westgeest T., Swaak T. Antinuclear antibody determination: the present state of diagnostic and clinical relevance. Scand J Rheumatol Suppl. 1985;56:78–92. doi: 10.3109/03009748509102067. [DOI] [PubMed] [Google Scholar]
  33. Smith K. A. T-cell growth factor. Immunol Rev. 1980;51:337–357. doi: 10.1111/j.1600-065x.1980.tb00327.x. [DOI] [PubMed] [Google Scholar]
  34. Swaak A. J., Groenwold J., Aarden L. A., Statius van Eps L. W., Feltkamp E. W. Prognostic value of anti-dsDNA in SLE. Ann Rheum Dis. 1982 Aug;41(4):388–395. doi: 10.1136/ard.41.4.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Tan E. M. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol. 1982;33:167–240. doi: 10.1016/s0065-2776(08)60836-6. [DOI] [PubMed] [Google Scholar]
  36. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  37. Tsokos G. C., Balow J. E. Phenotypes of T lymphocytes in systemic lupus erythematosus: decreased cytotoxic/suppressor subpopulation is associated with deficient allogeneic cytotoxic responses rather than with concanavalin A-induced suppressor cells. Clin Immunol Immunopathol. 1983 Feb;26(2):267–276. doi: 10.1016/0090-1229(83)90145-9. [DOI] [PubMed] [Google Scholar]
  38. Zubler R. H., Lowenthal J. W., Erard F., Hashimoto N., Devos R., MacDonald H. R. Activated B cells express receptors for, and proliferate in response to, pure interleukin 2. J Exp Med. 1984 Oct 1;160(4):1170–1183. doi: 10.1084/jem.160.4.1170. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES